Hycamtin Related Clinical Trials
Phase 1 Topotecan for Neoplastic Meningitis [Suspended]
Topotecan Vs. Topotecan + Etoposide Vs.Topotecan + Gemcitabine in Ovarian Cancer Therapy [Completed]
A Phase II Study of Topotecan in Children With Recurrent Wilms Tumor [Completed]
A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid Tumors [Completed]
Topotecan Weekly Versus Topotecan Day 1-5 in Patient With Platin-Resistant Ovarian Cancer [Active, not recruiting]
Efficacy Study of Weekly Topotecan With Cisplatin in Advanced Stage or Recurrent Cervical Cancer [Terminated]
Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma [Completed]
Oral Topotecan As A Radiosensitizing Agent In Rectal Cancer [Terminated]
Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial Cancer [Completed]
Efficacy Study of Weekly Taxotere and Topotecan for Recurrent Gynecologic (GYN) Cancers [Completed]
First-Line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And Paraplatin [Active, not recruiting]
A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors [Active, not recruiting]
A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer [Not yet recruiting]
Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung Cancer [Completed]
Study of Temsirolimus, Topotecan, and Bortezomib [Recruiting]
A Phase II Study of Weekly Docetaxel and Topotecan in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer [Completed]
Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy. [Active, not recruiting]
Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer [Active, not recruiting]
Ph I Trial of Oral Topotecan + Temo in Treatment of Pts w Malignant Gliomas [Recruiting]
Bortezomib and Topotecan in Treating Patients With Advanced Solid Tumors [Completed]
A Phase I Study Of Oral Topotecan And Lapatinib In Subjects With Advanced Solid Tumors [Not yet recruiting]
Therapy With Topotecan and Carboplatin by Patients With Relapsed Ovarian Cancer [Active, not recruiting]
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer [Active, not recruiting]
Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer [Active, not recruiting]
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer [Recruiting]
Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st-Line Extensive Disease Small Cell Lung Cancer [Completed]
Topotecan, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Cervical Cancer [Active, not recruiting]
Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer [Not yet recruiting]
Topotecan in Treating Patients With Relapsed Small Cell Lung Cancer [Active, not recruiting]
Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer [Active, not recruiting]
Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer [Terminated]
AMR PH GL 2007 CL 001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy [Recruiting]
Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies [Active, not recruiting]
Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer [Active, not recruiting]
Phase I, Dosage-Finding and PK Study of IV Topotecan and Erlotinib With Refractory Solid Tumors [Recruiting]
Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma [Active, not recruiting]
Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial Cancers [Not yet recruiting]
Topotecan Pharmacokinetic Characterization Study [Completed]
Amifostine Plus Topotecan in Treating Patients With Myelodysplastic Syndrome [Active, not recruiting]
Weekly Topotecan With Docetaxel in Recurrent Small Cell Lung Cancer [Terminated]
Topotecan for Irinotecan-Refractory SCLC [Active, not recruiting]
Phase I Study of GW572016 With Topotecan to Treat Advanced Solid Malignancies [Active, not recruiting]
Weekly Topotecan Therapy in Patients With Ovarian Cancer [Terminated]
Oral Topotecan to Treat Recurrent or Persistent Solid Tumors [Recruiting]
Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan [Recruiting]
Safety and Effectiveness of Topotecan HCl to Treat HIV-Infected Patients With AIDS-Related Progressive Multifocal Leukoencephalopathy (PML) [Completed]
Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan [Recruiting]
A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Carcinoma [Recruiting]
Phase I Study of Intrathecal Topotecan
A Phase I Topotecan Study in Subjects With Cancer and Impaired Renal Function [Recruiting]
A Pharmacokinetic and Phase II Study of Oral Cyclophosphamide and Topotecan in Children With Recurrent Solid Tumors [Recruiting]
Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma. [Recruiting]
Topotecan Plus Sargramostim in Treating Patients With Advanced Cancer [Active, not recruiting]
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
High-Dose Iodine I 131 Metaiodobenzylguanidine, Topotecan, and Peripheral Stem Cell Transplant in Treating Young Patients With Relapsed Stage 4 Neuroblastoma or Primary Resistant High-Risk Neuroblastoma [Not yet recruiting]
Paclitaxel, Carboplatin, and Topotecan in Patients With Ovarian Cancer
Topotecan, G-CSF, and Radiation Therapy in Treating Young Patients With Newly Diagnosed Brain Stem Glioma [Suspended]
UCN-01 and Topotecan in Treating Patients With Small Cell Lung Cancer That Relapsed or Progressed After Previous Chemotherapy [Recruiting]
Phase I Trial of Periocular Topotecan in Retinoblastoma
Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small Cell Lung Cancer [Completed]
Topotecan and Bortezomib in Treating Patients With Metastatic or Unresectable Cancer [Active, not recruiting]
Obatoclax Mesylate and Topotecan in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors [Recruiting]
Hycamtin Plus Carboplatin Versus Established Regimens for the Treatment of Ovarian Cancer Relapse [Recruiting]
UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer [Completed]
Topotecan, Ifosfamide and Carboplatin in Children and Young Adults With Solid Tumors [Recruiting]
UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer [Completed]
Phase I, Combining Oral Topotecan With Oral Pazopanib [Recruiting]
Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer [Recruiting]
Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer [Recruiting]
Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer [Recruiting]
Topotecan in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer [No longer recruiting]
Topotecan and Vinorelbine in Treating Patients With Recurrent Lung Cancer
Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer [Recruiting]
Topotecan in Treating Patients With Progressive or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer [No longer recruiting]
Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer [No longer recruiting]
Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer [No longer recruiting]
Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer [Completed]
Induction Chemotherapy Using Cyclophosphamide and Topotecan in Treating Patients Who Are Undergoing Autologous Peripheral Stem Cell Transplantation for Newly Diagnosed or Progressive Neuroblastoma [Completed]
Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer [Recruiting]
Topotecan, Vincristine, and Doxorubicin in Treating Young Patients With Refractory Stage 4 Neuroblastoma [Recruiting]
Topotecan in Treating Children With Refractory Leukemia [Completed]
Weekly Topotecan in Patients Treated for Metastatic Colorectal Cancer [No longer recruiting]
Topotecan in Combination With Docetaxel in Refractory and/or Advanced Solid Tumors [No longer recruiting]
Weekly Topotecan in the Second-Line Treatment of Small Cell Lung Cancer [No longer recruiting]
Safety Study of Intracerebral Topotecan for Recurrent Brain Tumors [Recruiting]
Topotecan in Treating Patients With Recurrent Brain Tumors [No longer recruiting]
Topotecan and Radiation Therapy in Treating Patients With Solid Tumors or Lymphoma [Completed]
Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer [No longer recruiting]
R115777 Plus Topotecan in Treating Patients With Advanced Solid Tumors [Completed]
Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma [No longer recruiting]
Topotecan in Treating Patients With Myelodysplastic Syndrome [No longer recruiting]
Weekly Topotecan in the First-Line Treatment of Elderly Patients With Small Cell Lung Cancer [No longer recruiting]
Topotecan in Treating Patients With Recurrent or Refractory Cancer of the Uterus [Completed]
Topotecan in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment [Completed]
Topotecan and Paclitaxel in Treating Patients With Recurrent or Metastatic Cancer of the Cervix [No longer recruiting]
Topotecan and Paclitaxel in Treating Patients With Recurrent or Refractory Small Cell Lung Cancer [Completed]
Weekly Topotecan in Combination With Carboplatin in Two Different Schedules for Refractory and/or Advanced Solid Tumors [Terminated]
Topotecan in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer [Recruiting]
Topotecan in Treating Patients With Refractory or Progressive Primary Malignant Brain Tumors [Recruiting]
Paclitaxel Plus Topotecan in Treating Patients With Solid Tumors [Completed]
Brain Metastases In ErbB2-Positive Breast Cancer [Recruiting]
|
